OPKO Health (OPK)
Market Price (12/24/2025): $1.32 | Market Cap: $1.0 BilSector: Health Care | Industry: Life Sciences Tools & Services
OPKO Health (OPK)
Market Price (12/24/2025): $1.32Market Cap: $1.0 BilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Low stock price volatilityVol 12M is 39% | Weak multi-year price returns2Y Excs Rtn is -64%, 3Y Excs Rtn is -75% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -214 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -33% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.96 | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -9.7%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -19%, Rev Chg QQuarterly Revenue Change % is -13% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -31%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -33% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22% | ||
| Key risksOPK key risks include [1] a history of operating losses and uncertain profitability, Show more. |
| Low stock price volatilityVol 12M is 39% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -64%, 3Y Excs Rtn is -75% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.96 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -214 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -33% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -9.7%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -19%, Rev Chg QQuarterly Revenue Change % is -13% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -31%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -33% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22% |
| Key risksOPK key risks include [1] a history of operating losses and uncertain profitability, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Q3 2025 Revenue Miss: OPKO Health reported third-quarter 2025 consolidated total revenues of $151.7 million, which represented a 12.6% decrease from the comparable period in 2024 and missed analyst expectations of $160.78 million.2. Decline in Diagnostics Revenue: The diagnostics segment experienced a decrease in revenue, primarily attributed to lower clinical test volumes due to the sale of certain BioReference assets in 2024 and the continued impact of the 2025 sale of oncology assets to Labcorp.
Show more
Stock Movement Drivers
Fundamental Drivers
The -9.0% change in OPK stock from 9/23/2025 to 12/23/2025 was primarily driven by a -7.2% change in the company's P/S Multiple.| 9232025 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.44 | 1.31 | -9.03% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 664.03 | 642.07 | -3.31% |
| P/S Multiple | 1.71 | 1.59 | -7.21% |
| Shares Outstanding (Mil) | 788.01 | 777.15 | 1.38% |
| Cumulative Contribution | -9.05% |
Market Drivers
9/23/2025 to 12/23/2025| Return | Correlation | |
|---|---|---|
| OPK | -9.0% | |
| Market (SPY) | 3.7% | 16.6% |
| Sector (XLV) | 13.2% | 37.4% |
Fundamental Drivers
The 1.6% change in OPK stock from 6/24/2025 to 12/23/2025 was primarily driven by a 26.2% change in the company's P/S Multiple.| 6242025 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.29 | 1.31 | 1.55% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 689.41 | 642.07 | -6.87% |
| P/S Multiple | 1.26 | 1.59 | 26.18% |
| Shares Outstanding (Mil) | 671.58 | 777.15 | -15.72% |
| Cumulative Contribution | -0.96% |
Market Drivers
6/24/2025 to 12/23/2025| Return | Correlation | |
|---|---|---|
| OPK | 1.6% | |
| Market (SPY) | 13.7% | 32.8% |
| Sector (XLV) | 16.4% | 33.2% |
Fundamental Drivers
The -13.2% change in OPK stock from 12/23/2024 to 12/23/2025 was primarily driven by a -11.9% change in the company's Shares Outstanding (Mil).| 12232024 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.51 | 1.31 | -13.25% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 711.41 | 642.07 | -9.75% |
| P/S Multiple | 1.47 | 1.59 | 7.55% |
| Shares Outstanding (Mil) | 694.62 | 777.15 | -11.88% |
| Cumulative Contribution | -14.47% |
Market Drivers
12/23/2024 to 12/23/2025| Return | Correlation | |
|---|---|---|
| OPK | -13.2% | |
| Market (SPY) | 16.7% | 37.7% |
| Sector (XLV) | 13.2% | 37.1% |
Fundamental Drivers
The 14.9% change in OPK stock from 12/24/2022 to 12/23/2025 was primarily driven by a 126.2% change in the company's P/S Multiple.| 12242022 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.14 | 1.31 | 14.91% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1220.19 | 642.07 | -47.38% |
| P/S Multiple | 0.70 | 1.59 | 126.17% |
| Shares Outstanding (Mil) | 750.40 | 777.15 | -3.57% |
| Cumulative Contribution | 14.77% |
Market Drivers
12/24/2023 to 12/23/2025| Return | Correlation | |
|---|---|---|
| OPK | -18.1% | |
| Market (SPY) | 48.4% | 26.3% |
| Sector (XLV) | 18.2% | 20.9% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OPK Return | 169% | 22% | -74% | 21% | -3% | -10% | -10% |
| Peers Return | � | � | -9% | 4% | -11% | 11% | � |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 114% |
Monthly Win Rates [3] | |||||||
| OPK Win Rate | 58% | 50% | 25% | 50% | 58% | 33% | |
| Peers Win Rate | � | 48% | 50% | 55% | 43% | 50% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| OPK Max Drawdown | -22% | -16% | -78% | -15% | -43% | -19% | |
| Peers Max Drawdown | � | � | -23% | -19% | -26% | -19% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: ACT, ALKS, LIVN, PRGO, PCRX. See OPK Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/23/2025 (YTD)
How Low Can It Go
| Event | OPK | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -82.5% | -25.4% |
| % Gain to Breakeven | 470.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -50.4% | -33.9% |
| % Gain to Breakeven | 101.7% | 51.3% |
| Time to Breakeven | 32 days | 148 days |
| 2018 Correction | ||
| % Loss | -84.9% | -19.8% |
| % Gain to Breakeven | 560.6% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -88.8% | -56.8% |
| % Gain to Breakeven | 791.7% | 131.3% |
| Time to Breakeven | 951 days | 1,480 days |
Compare to ACT, ALKS, LIVN, PRGO, PCRX
In The Past
OPKO Health's stock fell -82.5% during the 2022 Inflation Shock from a high on 2/1/2021. A -82.5% loss requires a 470.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
AI Analysis | Feedback
- It's like **Quest Diagnostics**, but with its own specialty pharmaceutical development and sales division.
- Imagine a specialty pharmaceutical company that also owns a major diagnostic lab, similar to **LabCorp**.
- A hybrid of **LabCorp** and a niche biotech company.
AI Analysis | Feedback
```html- Rayaldee: A prescription medication used to treat secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency.
- 4Kscore Test: A blood test that helps assess a man's risk of having high-grade prostate cancer, informing decisions about prostate biopsy.
- BioReference Laboratories: Provides comprehensive diagnostic laboratory testing services for healthcare providers and patients across a wide range of medical specialties.
- Claros 1: A proprietary point-of-care diagnostic platform designed for rapid, automated testing of various biomarkers directly in a clinical setting.
AI Analysis | Feedback
OPKO Health (OPK) primarily sells its pharmaceutical products and diagnostic services to other companies and organizations within the healthcare system, rather than directly to individual consumers. Based on OPKO Health's public filings (such as their 10-K reports), their major customers and customer categories include: 1. **Drug Wholesale Distributors:** These are the primary customers for OPKO's pharmaceutical products, including RAYALDEE. OPKO has indicated that its top three customers by revenue are U.S. drug wholesale distributors. While specific names are not disclosed by OPKO, major players in this sector that likely distribute OPKO's products include: * **McKesson Corporation** (MCK) * **Cardinal Health, Inc.** (CAH) * **Cencora, Inc.** (formerly AmerisourceBergen Corporation) (COR) 2. **Managed Care Organizations / Health Insurers:** For its BioReference Laboratories diagnostic services segment, OPKO's largest customer is a managed care organization. These organizations contract with laboratories to provide services to their insured members. Examples of major public managed care organizations include: * **UnitedHealth Group** (UNH) * **Elevance Health** (ELV) * **CVS Health** (which includes Aetna) (CVS) 3. **Healthcare Providers:** This broad category encompasses a multitude of entities that order diagnostic tests from BioReference Laboratories or purchase OPKO's diagnostic products (like the Claros 1 analyzer). This includes: * Hospitals * Physician Offices * Clinics * Urgent Care CentersAI Analysis | Feedback
nullAI Analysis | Feedback
Dr. Phillip Frost, Chief Executive Officer and Chairman
Dr. Frost has served as CEO and Chairman of OPKO Health, Inc. since March 2007. He is a serial entrepreneur in the healthcare and pharmaceutical industries. Dr. Frost founded IVAX Corporation in 1987 and served as its Chairman and CEO until its acquisition by Teva Pharmaceuticals in January 2006 for $7.4 billion or $7.6 billion. Prior to IVAX, he was Chairman of Key Pharmaceuticals, which he and a partner acquired in 1972 and later sold to Schering-Plough in 1986 for $835 million. He was also a significant investor in Continucare, a company sold for $416 million. Dr. Frost is involved with investment vehicles such as Frost Group LLC and Frost Gamma Investments Trust, and is Chairman of the Investment Committee at Peregrine Ventures, suggesting a pattern of involvement with investment-backed companies.
Adam Logal, Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer
Mr. Logal has served as OPKO's Senior Vice President and Chief Financial Officer since March 2014, and previously held positions as Vice President of Finance, Chief Accounting Officer, and Treasurer since March 2007. From 2002 to 2007, he held various senior management roles at Nabi Biopharmaceuticals, a publicly traded biopharmaceutical company, concluding as Senior Director of Accounting and Reporting. Mr. Logal also served as President of GeneDx, LLC, a former OPKO subsidiary, from July 2020 to June 2021.
Dr. Jane H. Hsiao, Vice Chairman and Chief Technical Officer
Dr. Hsiao has been the Vice Chairman and Chief Technical Officer of OPKO Health since 2007. Her previous experience includes serving as Vice Chairman-Technical Affairs of IVAX Corporation and as Chairman, CEO, and President of IVAX Animal Health. She also served as Chairman of Non-Invasive Monitoring Systems, Inc., and was its interim CEO in 2012.
Steven D. Rubin, Executive Vice President, Administration and Director
Mr. Rubin has been Executive Vice President, Administration at OPKO Health since May 2007 and a director since February 2007. He previously served as Senior Vice President, General Counsel, and Secretary of IVAX Corporation from August 2001 until September 2006. Mr. Rubin possesses extensive experience as a practicing lawyer, general counsel, and board member for several public companies.
Dr. Elias A. Zerhouni, President and Vice Chairman
Dr. Zerhouni was appointed President of OPKO Health and Vice Chairman of the Board on May 9, 2022. He was a co-founder and Chairman of ModeX Therapeutics Inc., a biotechnology company acquired by OPKO in May 2022. From 2012 to 2020, Dr. Zerhouni served as Chief Scientific Officer and Senior Vice President of Sanofi. He also led the NIH's Vaccine Research Center as its founding director for 14 years, from 1999 to 2012.
AI Analysis | Feedback
The key risks to OPKO Health (OPK) are:
- Operating Losses and Uncertainty of Profitability: OPKO Health has a history of operating losses, negative earnings, and negative free cash flow, raising concerns about its ability to achieve sustained profitability in the near future. The company's losses have increased over the past five years, and its revenue growth is trailing the broader market. This financial strain could challenge its ability to sustain operations and fund ongoing research and development initiatives.
- Reliance on Limited Proprietary Products and Research & Development Risks: The business is significantly reliant on a limited number of proprietary pharmaceutical products, such as Rayaldee and NGENLA. There is an inherent risk that these products may not achieve sufficient market acceptance or regulatory approval. Furthermore, the company faces substantial risks associated with its research and development activities, as many product candidates are in early development stages and may not ultimately result in commercially viable products.
- Regulatory and Reimbursement Pressures: OPKO Health operates in a complex and evolving regulatory environment, particularly concerning its laboratory operations and compliance with requirements such as CLIA. The company is susceptible to regulatory and reimbursement pressures, which can adversely impact its diagnostics segment and overall financial performance. Failure to maintain necessary regulatory licensures could lead to the suspension of diagnostic testing and significant financial penalties.
AI Analysis | Feedback
The increasing prevalence and sophistication of direct-to-consumer (DTC) at-home diagnostic kits and point-of-care (POC) testing solutions that offer greater convenience and speed compared to traditional centralized laboratory services, directly threatening OPKO's BioReference Laboratories segment.
AI Analysis | Feedback
OPKO Health's main products and services address several significant markets:
- VARUBI (rolapitant): For the prevention of chemotherapy-induced nausea and vomiting (CINV), the U.S. market opportunity is estimated to exceed $1 billion annually. Intravenous (IV) treatments for CINV constitute approximately 90% of this market.
- Rayaldee: This treatment for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) has an addressable market valued at $12 billion.
- NGENLA (somatrogon), formerly hGH-CTP: Indicated for pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone, the global growth hormone market is estimated at $5.5 billion and is projected to expand by up to 12.3% annually. The overall global growth hormone market was previously valued at more than $3 billion. Additionally, adult growth hormone deficiency (AGHD) affects approximately 50,000 individuals in the U.S.
- 4Kscore Test: This prostate cancer test operates within the global prostate cancer treatment market, which was valued at $6.89 billion in 2018 and is expected to reach $9.90 billion by 2026. The 4Kscore Test franchise specifically generated approximately $300 million in revenue for BioReference (an OPKO subsidiary) in 2024. This test is available in the United States, Europe, and other regions.
AI Analysis | Feedback
OPKO Health (NASDAQ: OPK) anticipates several key drivers for its future revenue growth over the next two to three years, stemming from strategic collaborations, advancements in its pharmaceutical pipeline, and growth within its diagnostics segment.
Here are 4 expected drivers of future revenue growth:
- Strategic Collaborations and Pipeline Advancements: OPKO Health expects significant revenue contributions from its research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This partnership could yield over $200 million in potential milestone payments for each program, with an overall value potentially exceeding $1 billion if multiple products are successful, alongside tiered royalties on global net sales. Regeneron is also responsible for funding all development and commercialization activities. Additionally, the progression of other pipeline candidates, such as the Merck-partnered Epstein-Barr virus vaccine, which is currently in a Phase 1 trial, and the advancement of OPK-88006 for obesity and MASH, are expected to drive future revenue through potential milestones and eventual product sales.
- Continued Growth of the 4Kscore Test: The 4Kscore Test franchise, a core part of OPKO's diagnostics business, is a significant growth driver. The test generated approximately $300 million in revenue in 2024 and has demonstrated strong performance, with volumes and revenues increasing by nearly 20% in the continuing business. Furthermore, the FDA's approval of a supplemental application, allowing the 4Kscore Test's use without digital rectal examination information, is expected to create further opportunities for growth.
- Increased Sales of Rayaldee: Sales of the pharmaceutical product Rayaldee have shown positive momentum, with revenue increasing to $7.5 million in the third quarter of 2025 compared to $5.8 million in the comparable prior-year period. Continued growth in Rayaldee sales is anticipated to contribute to pharmaceutical revenue.
- Optimized and Streamlined BioReference Health Diagnostics Operations: Following the sale of its oncology and related clinical assets to Labcorp, BioReference Health is now focused on its core clinical testing services in the New York and New Jersey region. This strategic streamlining is intended to enhance profitability and allow the company to capitalize on new revenue streams, such as direct-to-consumer, employer-based testing, and early-phase clinical trials, thereby improving its financial profile.
AI Analysis | Feedback
Share Repurchases
- In July 2024, OPKO Health's Board of Directors authorized a $100 million common stock repurchase program, which was subsequently increased by an additional $100 million in April 2025, bringing the total authorized capacity to $200 million.
- As of September 30, 2025, the company had repurchased approximately $73.8 million of its common stock under this program, with $126.2 million remaining authorized and available for future repurchases.
- During 2024, OPKO repurchased 25.8 million shares for $40.2 million, and in the third quarter of 2025, an additional 11.1 million shares were repurchased, contributing to approximately $33.5 million in repurchases for the full year 2025.
Share Issuance
- In 2024, OPKO Health completed a private offering of $250 million aggregate principal amount of 2044 Notes and issued $230 million of 3.75% Convertible Senior Notes due 2029.
- In the second quarter of 2025, the company completed an exchange agreement, issuing 121.4 million shares of common stock and approximately $63.5 million in cash to purchase $159.2 million of its outstanding convertible notes.
Inbound Investments
- In September 2024, OPKO Health sold select assets of BioReference to Labcorp for $237.5 million in cash.
- In October 2025, OPKO completed the sale of BioReference Health's oncology and related clinical assets to Labcorp for $225 million, which included $192.5 million paid at closing and up to $32.5 million in a performance-based earnout.
- In October 2025, ModeX Therapeutics, an OPKO subsidiary, entered a research collaboration with Regeneron Pharmaceuticals that includes an upfront payment and potential milestone payments exceeding $200 million for each program, with an overall potential value exceeding $1 billion, as Regeneron will fund all preclinical and clinical development and commercialization activities.
Outbound Investments
- OPKO Health expanded its pharmaceutical pipeline through the acquisition of ModeX Therapeutics, Inc., focusing on early-stage immune therapies for cancer and infectious diseases.
- In April 2025, OPKO made an $8 million equity investment in Entera Bio, purchasing approximately 3.7 million shares at $2.17 per share, as part of a collaboration to develop an oral GLP-1/glucagon peptide.
- On November 11, 2021, OPKO Health made a Series A round investment in HealthSnap.
Capital Expenditures
- Capital expenditures for the nine months ended September 30, 2025, were $9.6 million.
- Capital expenditures for the nine months ended September 30, 2024, were $19.6 million.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| OPKO Health Earnings Notes | ||
| With OPKO Health Stock Sliding, Have You Assessed The Risk? | Return | |
| OPKO Health (OPK) Operating Cash Flow Comparison | Financials | |
| OPKO Health (OPK) Debt Comparison | Financials | |
| OPKO Health (OPK) Net Income Comparison | Financials | |
| OPKO Health (OPK) EBITDA Comparison | Financials | |
| OPKO Health (OPK) Tax Expense Comparison | Financials | |
| OPKO Health (OPK) Revenue Comparison | Financials | |
| OPKO Health (OPK) Operating Income Comparison | Financials | |
| OPK Dip Buy Analysis |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to OPK. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 20.9% | 20.9% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 13.5% | 13.5% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 1.6% | 1.6% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for OPKO Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 27.11 |
| Mkt Cap | 2.7 |
| Rev LTM | 1,287 |
| Op Inc LTM | 194 |
| FCF LTM | 231 |
| FCF 3Y Avg | 192 |
| CFO LTM | 313 |
| CFO 3Y Avg | 252 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.7% |
| Rev Chg 3Y Avg | 3.5% |
| Rev Chg Q | 2.4% |
| QoQ Delta Rev Chg LTM | 0.6% |
| Op Mgn LTM | 9.2% |
| Op Mgn 3Y Avg | 8.3% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 19.2% |
| CFO/Rev 3Y Avg | 17.7% |
| FCF/Rev LTM | 15.8% |
| FCF/Rev 3Y Avg | 14.7% |
Price Behavior
Price Behavior
| Market Price | $1.31 | |
| Market Cap ($ Bil) | 1.0 | |
| First Trading Date | 11/02/1995 | |
| Distance from 52W High | -32.5% | |
| 50 Days | 200 Days | |
| DMA Price | $1.37 | $1.41 |
| DMA Trend | down | down |
| Distance from DMA | -4.7% | -7.2% |
| 3M | 1YR | |
| Volatility | 34.1% | 39.3% |
| Downside Capture | 78.09 | 118.79 |
| Upside Capture | 19.36 | 86.64 |
| Correlation (SPY) | 17.0% | 37.5% |
OPK Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.22 | 0.26 | 0.50 | 1.08 | 0.75 | 1.02 |
| Up Beta | 0.89 | 0.25 | -0.11 | 0.97 | 0.43 | 0.83 |
| Down Beta | 1.34 | 0.82 | 0.63 | 1.11 | 0.84 | 0.88 |
| Up Capture | -66% | -44% | 42% | 84% | 76% | 125% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 7 | 17 | 26 | 50 | 99 | 310 |
| Down Capture | 23% | 43% | 72% | 130% | 107% | 107% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 11 | 20 | 28 | 54 | 116 | 353 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of OPK With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| OPK | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -16.0% | 14.9% | 18.8% | 72.9% | 9.0% | 3.7% | -11.4% |
| Annualized Volatility | 39.1% | 17.3% | 19.5% | 19.2% | 15.3% | 17.2% | 35.0% |
| Sharpe Ratio | -0.36 | 0.64 | 0.76 | 2.72 | 0.36 | 0.05 | -0.14 |
| Correlation With Other Assets | 36.2% | 37.1% | 0.9% | 14.7% | 30.6% | 14.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of OPK With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| OPK | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -22.0% | 8.4% | 14.8% | 18.9% | 11.8% | 4.7% | 35.5% |
| Annualized Volatility | 58.2% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.9% |
| Sharpe Ratio | -0.19 | 0.40 | 0.70 | 0.98 | 0.51 | 0.16 | 0.62 |
| Correlation With Other Assets | 31.1% | 35.9% | 6.5% | 6.6% | 32.1% | 18.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of OPK With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| OPK | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -18.2% | 9.9% | 14.8% | 15.1% | 6.8% | 5.4% | 69.1% |
| Annualized Volatility | 65.0% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | -0.02 | 0.49 | 0.71 | 0.85 | 0.31 | 0.23 | 0.90 |
| Correlation With Other Assets | 32.5% | 33.4% | 5.7% | 10.8% | 25.8% | 11.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/29/2025 | 2.1% | -6.3% | -7.7% |
| 7/31/2025 | -7.0% | -3.9% | 7.8% |
| 2/27/2025 | 6.7% | 16.0% | 4.3% |
| 11/7/2024 | 4.8% | 11.7% | 9.0% |
| 8/7/2024 | 11.7% | 19.5% | 21.9% |
| 5/7/2024 | -3.8% | 0.4% | 3.1% |
| 2/27/2024 | -6.1% | -11.0% | 1.9% |
| 11/6/2023 | 0.0% | -4.5% | 19.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 11 | 16 |
| # Negative | 12 | 11 | 6 |
| Median Positive | 4.6% | 11.7% | 8.2% |
| Median Negative | -6.6% | -4.9% | -10.4% |
| Max Positive | 20.1% | 21.7% | 21.9% |
| Max Negative | -16.7% | -17.5% | -37.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10292025 | 10-Q 9/30/2025 |
| 6302025 | 7312025 | 10-Q 6/30/2025 |
| 3312025 | 5012025 | 10-Q 3/31/2025 |
| 12312024 | 3032025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8072024 | 10-Q 6/30/2024 |
| 3312024 | 5072024 | 10-Q 3/31/2024 |
| 12312023 | 3012024 | 10-K 12/31/2023 |
| 9302023 | 11062023 | 10-Q 9/30/2023 |
| 6302023 | 8032023 | 10-Q 6/30/2023 |
| 3312023 | 5032023 | 10-Q 3/31/2023 |
| 12312022 | 2272023 | 10-K 12/31/2022 |
| 9302022 | 11082022 | 10-Q 9/30/2022 |
| 6302022 | 8042022 | 10-Q 6/30/2022 |
| 3312022 | 5092022 | 10-Q 3/31/2022 |
| 12312021 | 3012022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.